N-isopropylquinoline-8-sulphonamide | 142598-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-isopropylquinoline-8-sulphonamide
• 英文别名: N-(propan-2-yl)quinoline-8-sulfonamide；N-propan-2-ylquinoline-8-sulfonamide
• CAS: 142598-00-3
• 化学式: C₁₂H₁₄N₂O₂S
• mdl: MFCD00754361
• 分子量: 250.321
• InChiKey: VVJUJBRDRJKVDA-UHFFFAOYSA-N

物化性质

• 沸点：
  416.2±37.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-isopropylquinoline-8-sulphonamide 在 platinum(IV) oxide 氢气 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 以80%的产率得到N-propan-2-yl-1,2,3,4-tetrahydroquinoline-8-sulfonamide
  参考文献：
  名称：

  Nagarajan, Kuppuswamy; Bhat, Ganapati A.; Rao, Vunnam Ranga, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1992, vol. 31, # 6, p. 310 - 315

  摘要：

  DOI：
• 作为产物：
  描述：

  喹啉-8-磺酰胺 在 sodium hydroxide 、 五氯化磷 、 碳酸氢钠 作用下， 以 氯苯 为溶剂， 反应 11.0h， 生成 N-isopropylquinoline-8-sulphonamide
  参考文献：
  名称：

  Nagarajan, Kuppuswamy; Bhat, Ganapati A.; Rao, Vunnam Ranga, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1992, vol. 31, # 6, p. 310 - 315

  摘要：

  DOI：

文献信息

• HIV REPLICATION INHIBITOR
  申请人：Shionogi & Co., Ltd.

  公开号：US20140249306A1

  公开（公告）日：2014-09-04

  The present invention provides a novel compound having an antiviral action, in particular, an HIV replication inhibiting action, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein, a broken line means the presence or absence of a bond; R 1 is substituted or unsubstituted alkyl etc., R 2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R 3 is a substituted or unsubstituted aromatic carbocyclic group; R 4 is a hydrogen atom etc.; R 5 is a substituted or unsubstituted aromatic carbocyclic group etc.; Y is a single bond etc.; R 6 is substituted or unsubstituted alkyl; R 7 is —Z—R 71 etc.; Z is —NR 72 —CO— etc.; R 71 is substituted or unsubstituted alkyl etc.; R 72 is a hydrogen atom etc.

  本发明提供了一种具有抗病毒作用的新化合物，特别是具有抑制HIV复制作用的化合物，以及一种药物组合物，特别是一种抗HIV药物。其中，虚线表示键的存在或不存在；R1是取代或未取代的烷基等，R2是取代或未取代的烷氧基等；n为1或2；R3是取代或未取代的芳香环烷基；R4是氢原子等；R5是取代或未取代的芳香环烷基等；Y是单键等；R6是取代或未取代的烷基；R7是—Z—R71等；Z是—NR72—CO—等；R71是取代或未取代的烷基等；R72是氢原子等。
• PYRUVATE KINASE M2 (PKM2) ACTIVATORS FOR USE IN THERAPY
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP2658543B1

  公开（公告）日：2019-02-20
• PYRUVATE KINASE R ACTIVATORS FOR USE IN THERAPY
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP2704720B1

  公开（公告）日：2019-08-07
• MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080008681A1

  公开（公告）日：2008-01-10

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20090005387A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.